A novel anticancer pharmacological agent targeting mitochondrial complex I

Gabriela Reyes-Castellanos; Alice Carrier

doi:10.1016/j.tips.2022.03.007

A novel anticancer pharmacological agent targeting mitochondrial complex I

Trends Pharmacol Sci. 2022 Sep;43(9):706-708. doi: 10.1016/j.tips.2022.03.007. Epub 2022 Apr 2.

Authors

Gabriela Reyes-Castellanos¹, Alice Carrier²

Affiliations

¹ Aix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM), F-13009 Marseille, France.
² Aix Marseille Université, CNRS, INSERM, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille (CRCM), F-13009 Marseille, France. Electronic address: [email protected].

PMID: 35382944
DOI: 10.1016/j.tips.2022.03.007

Abstract

Targeting metabolic reprogramming has proven successful in oncology, but this field requires better identification of drugs that inhibit mitochondrial metabolism in cancer cells. Recent work from Dr Wolf's group reveals that the primary target of the antitumor compound SMIP004-7 is mitochondrial complex I (NDUFS2 subunit), inhibition of which promotes anticancer immune surveillance.

Keywords: anticancer therapies; cancer metabolism; complex I; mitochondria; oxidative phosphorylation system; tumor microenvironment.

Publication types

Comment

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Electron Transport Complex I / metabolism
Humans
Mitochondria / metabolism
Neoplasms* / pathology

Substances

Antineoplastic Agents
Electron Transport Complex I